Global Vaccines Market Size By Type (Recombinant Vaccines, Viral Vaccines), By Application (Cholera, Hepatitis B), By Region, And Segment Forecasts, 2023 to 2032

The Global Vaccines Market was valued at USD 68.2 billion in 2023 and is projected to reach USD 122.5 billion by 2031, expanding at a CAGR of 7.5% during the forecast period of 2023–2031. The increasing prevalence of infectious diseases, rising government immunization initiatives, and the emergence of advanced vaccine technologies are key factors driving this market's robust growth. The post-pandemic shift towards preventive healthcare, combined with rising awareness and favorable funding, has further accelerated the adoption of both pediatric and adult vaccines globally.

Drivers:

1. Rise in Infectious and Chronic Diseases:

The growing burden of infectious diseases such as influenza, HPV, hepatitis, and emerging zoonotic diseases is propelling the demand for effective vaccination programs. Governments and healthcare bodies are actively promoting immunization to reduce disease incidence and control healthcare costs.

2. Technological Advancements in Vaccine Development:

Progress in recombinant DNA technology, mRNA-based vaccines, and nanoparticle delivery systems has enabled faster development of effective vaccines with improved safety and efficacy profiles.

3. Expanding Global Immunization Programs:

Major global health agencies like WHO, UNICEF, and GAVI are investing heavily in expanding immunization programs in low- and middle-income countries, widening vaccine access and coverage.

Restraints:

1. High Cost of Development and Regulatory Challenges:

Vaccine development involves long and costly R&D cycles, clinical trials, and strict regulatory requirements. These barriers may limit entry for smaller manufacturers and delay time-to-market.

2. Vaccine Hesitancy:

Despite scientific backing, a growing segment of the population remains hesitant to vaccinate due to misinformation, cultural beliefs, and distrust in pharmaceutical companies, posing a challenge to market expansion.

Opportunity:

1. mRNA and Personalized Vaccines:

The successful rollout of mRNA vaccines during COVID-19 has opened new avenues for personalized vaccines targeting cancer, rare diseases, and chronic infections, presenting major commercial opportunities.

2. Growing Demand in Emerging Economies:

With rising healthcare infrastructure, awareness, and disease burden in countries like India, Brazil, and Indonesia, emerging economies represent high-growth regions for vaccine manufacturers.

Market by System Type Insights:

By system type, Inactivated & Subunit Vaccines accounted for the largest market share in 2023, owing to their long-standing use, proven safety, and effectiveness. However, the mRNA Vaccines segment is expected to witness the fastest growth through 2031, fueled by technological breakthroughs and increasing investments in next-generation vaccine platforms.

Market by End-use Insights:

Pediatric end-use dominated the market in 2023, with robust national immunization programs ensuring high vaccination rates among children. However, the Adult & Geriatric segment is poised for significant growth, driven by rising incidence of diseases in aging populations and increased focus on preventive health measures.

Market by Regional Insights:

In 2023, North America led the vaccines market, supported by a strong pharmaceutical industry, high healthcare spending, and extensive immunization coverage. Asia-Pacific is expected to register the fastest growth rate during the forecast period, driven by large population bases, government initiatives, and rising investments in public health infrastructure.

Competitive Scenario:

Key players in the global vaccines market include Pfizer Inc., GlaxoSmithKline plc, Moderna Inc., Sanofi S.A., Johnson & Johnson, Merck & Co., Inc., Bharat Biotech, CSL Limited, AstraZeneca plc, and Serum Institute of India. These companies are focusing on partnerships, R&D collaborations, and expanding production capacities to meet the growing global demand.

Recent Developments:

In 2024, Pfizer and BioNTech announced the initiation of clinical trials for a new universal influenza mRNA vaccine.

In 2023, Moderna expanded its portfolio with cancer vaccine candidates using the same mRNA platform used for COVID-19.

In 2022, Serum Institute of India launched a quadrivalent influenza vaccine aimed at affordable distribution across African and South Asian markets.

Scope of Work – Global Vaccines Market

Key Market Developments:

2023: GSK launched a next-gen shingles vaccine with improved antigen presentation for older adults.

2024: Sanofi and BioNTech formed a strategic partnership to co-develop vaccines for dengue and Zika.

2025: Bharat Biotech announced successful trials for an intranasal COVID-19 booster, focusing on ease of administration.

FAQs:

1) What is the current market size of the Global Vaccines Market?

The Global Vaccines Market was valued at USD 68.2 billion in 2023.

2) What is the major growth driver of the Global Vaccines Market?

The rising burden of infectious diseases and growing government immunization initiatives are key growth drivers.

3) Which is the largest region during the forecast period in the Global Vaccines Market?

North America accounted for the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Vaccines Market?

The Inactivated & Subunit Vaccines segment held the largest share in 2023.

5) Who are the key market players in the Global Vaccines Market?

Key players include Pfizer Inc., Moderna Inc., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., and Serum Institute of India.